Plasmid DNA Vaccines Manufacturing
Plasmid DNA Vaccines Process
Plasmid DNA (pDNA) is an important component of viral vector therapies. These circular DNA molecules can be used as the therapeutic transgene, to code for the viral capsid or as the vaccine itself. DNA vaccines have been approved for use in animals and have been developed against the SARS-CoV-2 virus. pDNA is also used as the starting material for mRNA vaccines.
pDNA manufacturing presents several challenges. Production suffers from low productivity of microbial fermentation. Additionally, the purification process is complicated by the fact that the bacterial lysate is highly viscous and contains contaminants with properties similar to pDNA, leading to low resolution separation. These challenges can be overcome with use of an end-to-end platform consisting of advanced single-use technologies.
Featured Categories
Emprove® Program: The smart way to master compliance and control. Complementing our product portfolio, the Emprove® Program provides convenient access to reliable technical, regulatory and supply information in Emprove® Dossiers to support your risk assessment continuum.
Enhance biopharma safety and compliance with our virus inactivation solutions, including pasteurization and low pH treatment.
The Mobius® Bioreactor family includes the bench scale (2 mL and 3 L), pilot, clinical and commercial manufacturing (50 – 2,000 L) single-use bioreactors that enable cell culturing capabilities from early process development through commercial batch production.
Explore Mobius® single-use mixing solutions for pharmaceutical ingredient blending and process solution preparation.
To continue reading please sign in or create an account.
Don't Have An Account?